Truepoint Inc. Makes New Investment in DENTSPLY SIRONA Inc. $XRAY

Truepoint Inc. bought a new stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 110,000 shares of the medical instruments supplier’s stock, valued at approximately $1,396,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in DENTSPLY SIRONA by 4.1% during the third quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock valued at $279,263,000 after acquiring an additional 869,566 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC raised its holdings in shares of DENTSPLY SIRONA by 8.0% during the 2nd quarter. Lazard Asset Management LLC now owns 10,107,657 shares of the medical instruments supplier’s stock valued at $160,508,000 after purchasing an additional 745,421 shares in the last quarter. State Street Corp lifted its stake in shares of DENTSPLY SIRONA by 5.5% in the 2nd quarter. State Street Corp now owns 7,099,906 shares of the medical instruments supplier’s stock valued at $113,868,000 after purchasing an additional 369,876 shares during the last quarter. Finally, Edmond DE Rothschild Holding S.A. boosted its holdings in DENTSPLY SIRONA by 6.0% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 3,087,300 shares of the medical instruments supplier’s stock worth $49,026,000 after purchasing an additional 173,900 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

XRAY has been the subject of a number of analyst reports. Wells Fargo & Company boosted their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $13.00 to $17.00 in a report on Thursday, February 19th. Stifel Nicolaus set a $13.00 price target on shares of DENTSPLY SIRONA in a research report on Thursday, November 6th. Robert W. Baird upped their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Finally, Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday. Three analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $14.42.

DENTSPLY SIRONA Stock Performance

NASDAQ:XRAY opened at $13.33 on Friday. The firm has a market capitalization of $2.66 billion, a PE ratio of -4.44, a price-to-earnings-growth ratio of 1.57 and a beta of 0.97. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA Inc. has a 12-month low of $9.85 and a 12-month high of $17.18. The firm has a 50-day moving average price of $12.61 and a 200 day moving average price of $12.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The company had revenue of $961.00 million during the quarter, compared to the consensus estimate of $926.40 million. During the same quarter in the prior year, the company posted $0.26 earnings per share. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 9th. Shareholders of record on Friday, December 26th were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date was Friday, December 26th. DENTSPLY SIRONA’s dividend payout ratio is -21.33%.

Insider Transactions at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Gregory T. Lucier sold 82,200 shares of DENTSPLY SIRONA stock in a transaction on Monday, December 8th. The stock was sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.50% of the stock is owned by corporate insiders.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.